Compare Heron Therapeutics Inc (HRTX) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs State Street SPDR S&P Homebuilders ETF — how do they compare? Heron Therapeutics Inc trades at $0.38 (market cap $68.01M), while State Street SPDR S&P Homebuilders ETF trades at $94.84 (market cap $1.49B). The key difference: State Street SPDR S&P Homebuilders ETF is far larger — about 21.9× Heron Therapeutics Inc's market cap, and State Street SPDR S&P Homebuilders ETF is more actively traded (2,445,587 versus 1,891,941). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and State Street SPDR S&P Homebuilders ETF for 33 Days on average.
| HRTX | XHB | |
|---|---|---|
Market Cap | $68.01M | $1.49B |
Volume | 1,891,941 | 2,445,587 |
Sector | Health | Broad Market / Factor |
52-Week High | $1.49 | $121.36 |
52-Week Low | $0.27 | $94.86 |
Typical Hold Time | 35 Days | 33 Days |
Enterprise Value | $174.75M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
XHB, the SPDR S&P Homebuilders ETF, trades at $94.65, down 0.25% on the day. Technical indicators are bearish, with moving averages signaling sell pressure and oscillators neutral. The ETF tracks the homebuilding sector, which faces headwinds from high mortgage rates but potential tailwinds from new housing affordability legislation and institutional interest.
The outlook for XHB is mixed, balancing sector-specific risks like rising rates against legislative support and valuation opportunities. Investment appeal hinges on a housing market recovery, with risks including economic sensitivity and inventory constraints. Sentiment is cautious but notes historical buying signals at current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
